Back

Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: HFpEF issues Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Joseph Kassab

UT Southwestern Medical Center, Dallas (United States of America)

5 More presentations in this session

Presentation thumbnail
Insights into pulmonary remodelling in heart failure with preserved ejection fraction through transpulmonary biomarker gradients
Doctor M. Dagan (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Small left ventricle in patients with heart failure with preserved ejection fraction is associated with higher mortality
Doctor Y. Nakagawa (Kawanishi, JP)
Abstract Slides Video
Presentation thumbnail
Phenogrouping HFpEF trajectories identifies early and end-stage subtypes: a multicentre study using natural language processing
Doctor S. Brown (London, GB)
Abstract Slides Video
Presentation thumbnail
Gender-specific outcomes and treatment responses in elderly HFpEF patients: a comprehensive single-center retrospective study
Doctor K. Shi (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Characteristics of pulmonary hypertension in adults with left ventricular diastolic dysfunction
Doctor S. Ratwatte (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
HFpEF issues

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies
thumbnail
Congress Presentation
In-hospital course of patients with heart failure with Improved ejection fraction in the DELIVER Trial
thumbnail
Congress Presentation
Comparison of dapagliflozin 10 mg versus empagliflozin 10 mg in heart failure patients without type 2 diabetes mellitus on top of triple guideline-directed medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources